Penghua CSI Health Care Index Fund(LOF)-A

HKEX Discloses: JPMorgan Increases Short Position in Wuxi AppTec H-Share to 3.34% on May 14

Schroders PLC Increased Holdings in Hengrui Medicine by 663,000 Shares on May 12 at Cost of Approx. 45.55 Million HKD

BlackRock Increases Stake in Wuxi AppTec H-Shares to 6.32%

Bristol Myers Squibb and Hengrui Medicine Reach Billions-Deal to Co-Develop Drugs and Conduct Early Clinical Trials in China

Orient Securities: WuXi AppTec 2026 Q1 Net Profit 4.65B, Maintains Buy Rating with Target Price 140.16 Yuan

Hengrui Medicine and BMS Reach $15.2 Billion Super BD Deal

Hengrui Medicine's Subsidiary Receives Approval for SHR-3079 Injection Clinical Trials

Hengrui Medicine Receives Approval for Three Drugs' Clinical Trials

Jiangsu Hengrui Medicine Signs $950 Million Global R&D Agreement with Bristol-Myers Squibb

Hengrui Medicine and Braveheart Bio Report Positive Phase 2 Results for HRS/BHB-1893 in Treating nHCM

Hengrui Medicine Receives Approval for Two Drug Clinical Trials

Hengrui Pharmaceutical Obtains Clinical Trial Approval Notifications for Multiple New Drugs

Huaren Pharmaceutical Receives Approval for Clinical Trials of HRS-3005

Hengrui Pharmaceutical Repurchased 12,056,200 A-shares in April

Acceleration of Chinese Innovative Drugs Internationalization and Wuxi Biologics' Exceeding Expectations in Q1 2026

BlackRock Increases Holding in Wuxi Biologics H Shares

HSBC Upgrades Wuxi Biologics Rating and Target Price

Goldman Sachs Analyst Gives Buy Rating to WuXi AppTec's H Shares

JPMorgan Raises Target Price for WuXi AppTec to HKD 172

161726

512290

160635

Guotai CSI Bio-medicine ETF (512290) rose over 1% on April 14, with the focus on innovative drugs going overseas and value realization becoming the market highlight. Xiangcai Securities pointed out that the 2025 global pharmaceutical sales TOP 100 list shows that the industry landscape is undergoing profound changes, with market growth momentum shifting from tumor immunity to chronic diseases such as metabolic disorders, particularly the rise of GLP-1 drugs. Technological iteration has spawned new growth poles, and innovative therapies have become the new engine of growth. This ETF tracks the CSI Bio-medicine Index, reflecting the overall performance of listed companies in the biopharmaceutical sector. Risk warning: Individual stock analysis does not constitute investment advice; investment should be approached with caution

腾讯新闻 - 财经

China Merchants CNI BIOMEDICINE Index Fund-A

Guotai CSI Bio-medicine ETF

XIANGCAI

Guotai Bio-medicine ETF (512290) rose over 1%, with the focus on innovative drugs going overseas and value realization becoming the core highlight

516820

The National Medical Products Administration released 26 industry standards for medical devices, attracting attention to medical innovation ETFs. The constituents of the CSI Medicine and Medical Device Innovation Index showed mixed performance, with the latest quote for the medical innovation ETF at 0.36 yuan and an average daily trading volume of 51.0169 million yuan. The National Medical Products Administration approved the registration of BrainCo's brain-computer interface products, marking the entry of the world's first invasive brain-computer interface medical device into clinical application. Kaiyuan Securities pointed out that the brain-computer interface industry will accelerate its development, and related companies are expected to speed up the clinical trial process

iShares US Pharma

SPDR Pharmac

First Trust NYSE Arca Biotech Index Fd

Ping An CSI Medicine and Medical Device Innovation ETF

VanEck Biotech ETF

SPDR S&P Biotech

Minsheng Royal CSI Biotechnology Theme ETF

ChinaAMC SSE Health Care ETF Initiating Fund

Direxion S&P Biotech Bull 3X

iShares Biotechnology ETF

E Fund CSI 300 Health Care ETF

Invesco Biotechnology & Genome ETF

ALPS Medical Breakthrough

GF Fund CSI Medical Service ETF

Invesco Pharmaceuticals ETF

Guotai SSE STAR Brand Name Drug ETF

Guotai CSI Medical Service ETF

GF CSI All Share Health Care ETF

VanEck Pharmaceutical ETF

China Merchants CSI Biotechnology Theme ETF

The Drug Administration announced 26 industry standards for medical devices, and medical innovation ETFs are receiving significant attention

560600

003008

159898

The first invasive brain-computer interface has been approved, with Borui Kang Medical's implanted brain-computer interface receiving NMPA approval for market launch, marking the entry of the domestic brain-computer interface industry into the clinical application stage. The latest quote for the Medical Innovation ETF (516820) is 0.36 yuan, with an average daily transaction of 51.36 million yuan over the past year, reaching a scale of 1.842 billion yuan. The constituents of the CSI Medicine and Medical Device Innovation Index (931484) show mixed performance, and Century Securities recommends paying attention to medical device companies with invasive brain-computer interface technology

Founder Fubon CSI Medicine and Medical Device Innovation ETF

KETOP

China Merchants CSI All Share Medical Apparatus and Instruments ETF

The first certificate for invasive brain-machine interfaces has been issued, and medical innovation ETFs are attracting attention

002001

The medical innovation ETF is trending upwards, with continuous positive policies being released. The CSI Medicine and Medical Device Innovation Index rose by 0.01%, and constituent stock NHU increased by 4.66%. Jiangsu Province has released an innovation development plan for the brain-computer interface industry, aiming to cultivate 30 application scenarios by 2030. Biomedicine has been elevated to an emerging pillar industry, with an estimated total of 157 innovative drug transactions expected by 2025, amounting to approximately USD 135.7 billion. The medical innovation ETF closely tracks the CSI Medicine and Medical Device Innovation Index, reflecting the overall performance of listed pharmaceutical and medical device companies. Risk warning: Investment should be cautious

The medical innovation ETF is trending upward, with continuous positive policies being released

医药生物

159859

399441

Benefiting from the recovery of industry prosperity and favorable policies, more than 50 A-share biomedicine companies are expected to achieve profitability by 2025. According to Wind data, as of January 26, over 90 companies have released performance forecasts, among which 53 companies expect to be profitable, 14 companies expect to double their net profits, 10 companies expect to turn losses into profits, and 14 companies expect to reduce their losses year-on-year

Wallstreetcn

Tianhong CNI BIOMEDICINE ETF

CNI BIOMEDICINE

With the recovery of industry prosperity and favorable policies, over 50 biomedicine A-share companies are expected to report profits in 2025

Penghua CSI Health Care Index Fund(LOF)-A(160635.SZ)

Guotai Bio-medicine ETF (512290) rose over 1%, with the focus on innovative drugs going overseas and value realization becoming the core highlight

The Drug Administration announced 26 industry standards for medical devices, and medical innovation ETFs are receiving significant attention

The first certificate for invasive brain-machine interfaces has been issued, and medical innovation ETFs are attracting attention

The medical innovation ETF is trending upward, with continuous positive policies being released

With the recovery of industry prosperity and favorable policies, over 50 biomedicine A-share companies are expected to report profits in 2025